AgingResearch.NewsJoin free

Phase 2Active, not recruiting

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Sponsor
Abramson Cancer Center at Penn Medicine (Academic or other)
Enrolment
96 planned
Conditions
Breast Cancer
Interventions
HCQ; Avelumab; Palbociclib
Ages
adults, older adults
Registry
NCT04841148

Full record on ClinicalTrials.gov

From the registry

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

Primary outcomes

  • Determine the efficacy of HCQ or Avelumab, alone or in combination with Palbociclib, in eradicating DTCs

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered